Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1110962

registered interest
date	10/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Equipment: Computers
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the effect of the regulation of section 6 of the Health and Safety at Work Act 1974 on medical devices containing computers.
tabling member constituency	Vauxhall
tabling member printed	Kate Hoey
uin	243321
answer	answer is ministerial correction date of answer 15/04/2019 answer text <p>The Department has not made any assessment of the effect of the regulation of section 6 of the Health and Safety at Work Act 1974 on medical devices containing computers.</p><p> </p><p>Section 6 of the Health and Safety at Work Act 1974 places duties on any person who designs, manufacturers, imports or supplies any article for use at work to ensure that it will be safe and without risks to health. In general this applies to all devices used in the workplace but there are exceptions, such as medical devices, which are regulated by specific regulations that set out more detailed duties.</p><p> </p><p>The Medical Devices Regulations 2002 deal with the design, manufacture, import or supply of medical devices, including those which may contain computers/software. It is for the designer, manufacturer, importer or supplier to demonstrate that their product is safe. These regulations transpose the requirements of the following European Directives concerning product safety for medical devices:</p><p>- Council Directive 90/385/EEC on Active Implantable Medical Devices (AIMDD)(1990);</p><p>- Council Directive 93/42/EEC on Medical Devices (MDD)(1993); and</p><p>- Council Directive 98/79/EC on In Vitro Diagnostic Medical Devices (IVDMD)(1998).</p><p> </p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medical devices in the United Kingdom. The following link provides more information on MHRA and its role:</p><p> </p><p><a href="https://www.gov.uk/topic/medicines-medical-devices-blood/medical-devices-regulation-safety" target="_blank">https://www.gov.uk/topic/medicines-medical-devices-blood/medical-devices-regulation-safety</a></p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 15/04/2019 14:26:12 answering member 4065 label Biography information for Jackie Doyle-Price
tabling member	210 label Biography information for Kate Hoey

1110964

registered interest
date	10/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Inflammatory Bowel Disease
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the change in the number of people diagnosed with Crohn's disease between 2008 and 2018.
tabling member constituency	East Londonderry
tabling member printed	Mr Gregory Campbell
uin	243360
answer	answer is ministerial correction date of answer 17/04/2019 answer text <p>Information regarding number of patients diagnosed with Crohn’s disease in any one year is not available, and therefore no estimate has been made. The National Institute for Health and Care Excellence guidance, ‘Crohn’s disease: management’, updated in 2016 to reflect the last available evidence, states that at least 115,000 people in the United Kingdom have the condition.</p><p> </p><p>The guidance can be found at the following link:</p><p> </p><p><a href="http://www.nice.org.uk/guidance/cg152/resources/crohns-disease-management-pdf-35109627942085" target="_blank">www.nice.org.uk/guidance/cg152/resources/crohns-disease-management-pdf-35109627942085</a></p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 17/04/2019 12:04:18 answering member 4455 label Biography information for Seema Kennedy previous answer version 114109 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
tabling member	1409 label Biography information for Mr Gregory Campbell

1110965

registered interest
date	10/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Infant Mortality
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 1 May 2018 to Question 137006, whether he commission an assessment of the reasons for the trends in data provided by the Office for National Statistics in relation to infant mortality rates in households in different income quintiles.
tabling member constituency	Birkenhead
tabling member printed	Frank Field
uin	243351
answer	answer is ministerial correction date of answer 15/04/2019 answer text <p>We have not commissioned such an assessment. Public Health England (PHE) monitors trends in infant mortality at national and local level as part of the Public Health Outcomes Framework, which is statutory guidance for local authorities and published on PHE’s fingertips platform. Inequalities in infant mortality are monitored by decile of deprivation, which is updated every year and available at the following link:</p><p><a href="https://fingertips.phe.org.uk/profile/public-health-outcomes-framework/data#page/7/gid/1000044/pat/6/par/E12000001/ati/102/are/E06000005/iid/92196/age/2/sex/4" target="_blank">https://fingertips.phe.org.uk/profile/public-health-outcomes-framework/data#page/7/gid/1000044/pat/6/par/E12000001/ati/102/are/E06000005/iid/92196/age/2/sex/4</a></p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 15/04/2019 12:45:51 answering member 4065 label Biography information for Jackie Doyle-Price
tabling member	478 label Biography information for Frank Field

1110984

registered interest
date	10/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Urinary Tract Infections: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 5 April 2019 to Question 237733, what representations he has received on the capability of NHS urinary trace infection screening tests to detect bacteria hidden in the bladder's lining.
tabling member constituency	Tooting
tabling member printed	Dr Rosena Allin-Khan
uin	243537
answer	answer is ministerial correction date of answer 17/04/2019 answer text <p>A search of the Department’s Ministerial correspondence database has identified four items of correspondence received on the capability of National Health Service urinary tract infection (UTI) screening tests to detect bacteria in the bladder's lining during the past 12 months. This figure represents correspondence received by the Department’s Ministerial correspondence unit only.</p><p>In November 2018 Public Health England published guidance on the diagnosis of UTIs. This guidance states that “no individual or combination (of symptoms or dipstick) are completely reliable in diagnosing UTI, thus severity of symptoms and safety-netting are important.”</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 17/04/2019 12:22:09 answering member 4455 label Biography information for Seema Kennedy
tabling member	4573 label Biography information for Dr Rosena Allin-Khan

1110991

registered interest
date	10/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Department of Health and Social Care: Brexit
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has deprioritised any Statutory Instruments in relation to the UK leaving the EU; and if he will publish the criteria his Department uses to deprioritise those Instruments.
tabling member constituency	Walsall South
tabling member printed	Valerie Vaz
uin	243433
answer	answer is ministerial correction date of answer 16/04/2019 answer text <p>The Department has not deprioritised any European Union exit Statutory Instruments (SIs).</p><p> </p><p>Our objective has always been to have a functioning statute book in place by ‘exit day’ and to ensure that the most critical secondary legislation was made by this point. Each SI was carefully considered on a case-by-case basis, enabling the Department to lay the critical secondary legislation required before we exit the EU.</p><p> </p><p>Given the extension to Article 50, the Department will consider whether any further EU exit SIs will need to be brought forward to amend any EU Regulations which have come into force since the original EU Exit SI programme was finalised, to ensure a functioning statute book ahead of a potential ‘no deal’ exit. The Department will keep this under careful review.</p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 16/04/2019 14:37:25 answering member 1585 label Biography information for Stephen Hammond previous answer version 114111 answering member constituency Wimbledon answering member printed Stephen Hammond answering member 1585 label Biography information for Stephen Hammond
tabling member	4076 label Biography information for Valerie Vaz

1111006

registered interest
date	10/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans he has to lower the mammogram screening age to help prevent breast cancer among younger women.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	243437
answer	answer is ministerial correction date of answer 17/04/2019 answer text <p>There are currently no plans to lower the age of the National Health Service Breast Screening Programme, which offers all women between the ages of 50 to their 71<sup>st</sup> birthday the opportunity to be screened every three years for breast cancer.</p><p>The United Kingdom National Screening Committee awaits the publication of the Age Extension Trial which is looking at the benefits and harms of screening outside the recommended screening age. It is expected that the trial will report in 2026.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 17/04/2019 12:02:04 answering member 4455 label Biography information for Seema Kennedy
tabling member	4079 label Biography information for Julian Sturdy

1111007

registered interest
date	10/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to reduce rates of breast cancer in women with BRCA 1 and 2 genes.
tabling member constituency	York Outer
tabling member printed	Julian Sturdy
uin	243438
answer	answer is ministerial correction date of answer 17/04/2019 answer text <p>NHS England commissions breast cancer screening services, according to the published national service specifications. The Breast Cancer Screening Programme service specification includes provision for the surveillance of high risk women for early detection of breast cancer (including those with the BRCA 1 and 2 genes) and timely referral to treatment as appropriate. Specifically, following an assessment by specialised services, and referral from a genetics or oncology service, high risk women who meet the eligibility criteria (as outlined in the published guidance) will be included in the screening programme at a younger age and according to different protocols to the general population.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 17/04/2019 12:18:14 answering member 4455 label Biography information for Seema Kennedy
tabling member	4079 label Biography information for Julian Sturdy

1111021

registered interest
date	10/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Records
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve data sharing between private and NHS hospitals.
tabling member constituency	Coventry South
tabling member printed	Mr Jim Cunningham
uin	243337
answer	answer is ministerial correction date of answer 15/04/2019 answer text <p>The Acute Data Alignment Programme (ADAPt) was established on 9 January 2018, and was launched in June 2018. The ADAPt Programme is jointly led by NHS Digital and the Private Healthcare Information Network (PHIN) in partnership with stakeholders from the Department, NHS Improvement, NHS England, and the Care Quality Commission.</p><p> </p><p>The programme has served to develop good working relationships between PHIN, NHS Digital and key stakeholders. The first phase focuses on ensuring that independent hospitals and National Health Service private patient units are submitting robust, complete and accurate data to PHIN, and that performance measures already required to be published by Order of the Competition and Markets Authority can be achieved as quickly as possible. The second phase will ensure the data flows from independent providers into NHS Digital, just as it does from NHS providers, enabling consistency in measurement and understanding of both risk of harm and health outcomes for patients wherever they are treated.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 15/04/2019 12:38:56 answering member 4065 label Biography information for Jackie Doyle-Price
tabling member	308 label Biography information for Mr Jim Cunningham

1111101

registered interest
date	10/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent estimate his Department has made of the number of NHS prescriptions for medicine in which THC is the dominant ingredient.
tabling member constituency	Newcastle-under-Lyme
tabling member printed	Paul Farrelly
uin	243361
answer	answer is ministerial correction date of answer 17/04/2019 answer text <p>The Department has made no estimate of the number of National Health Service prescriptions for cannabis-based products in which delta-9-tetrahydrocannabinol (THC) is the dominant ingredient.</p><p> </p><p>NHS England is using extant systems to monitor use of the newly rescheduled unlicensed cannabis-based products for medicinal use in England. In England, these systems monitor the number of items dispensed and associated costs in primary care and the volume of products used and associated cost in secondary care. NHS England Controlled Drug Accountable Officers are also collecting local intelligence in both the NHS and independent sector.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 17/04/2019 11:49:19 answering member 4455 label Biography information for Seema Kennedy previous answer version 114110 answering member constituency South Ribble answering member printed Seema Kennedy answering member 4455 label Biography information for Seema Kennedy
tabling member	1436 label Biography information for Paul Farrelly

1111106

registered interest
date	10/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what advice has been issued to Clinical Commissioning Groups on the criteria for the prescription of medicinal cannabis.
tabling member constituency	Leigh
tabling member printed	Jo Platt
uin	243575
answer	answer is ministerial correction date of answer 17/04/2019 answer text <p>The Chief Medical Officer and NHS England issued a letter on the 31 October 2018, and a supplementary letter on 20 November 2018, providing guidance to clinicians, the National Health Service and independent organisations following the rescheduling of cannabis-based products for medicinal use on 1 November 2018. This signposts interim guidance issued by the Royal College of Physicians, British Paediatric Neurology Association and Association of British Neurologists.</p><p> </p><p>Furthermore, the National Institute for Health and Care Excellence (NICE), has been commissioned to develop guidelines on the prescribing of cannabis-based medicinal products by October 2019. The guidance will focus on four indications: chronic pain, intractable nausea and vomiting, treatment-resistant epilepsy and spasticity. It will be based on the best available international evidence and produced using NICE’s world-renowned process for delivering such guidelines. This guidance will update and replace the interim guidance.</p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 17/04/2019 12:26:52 answering member 4455 label Biography information for Seema Kennedy
tabling member	4673 label Biography information for Jo Platt